Counterfeit medicines are a serious and fast expanding threat for the consumer’s health and the pharmaceutical manufacturers business.


The aim of this research collaboration is to add anti-counterfeiting and track & trace technology to the product level that goes beyond the state-of-the-art security approach on the packaging level.

The project SAVEmed will bring a solution for the counterfeiting and the illegal re-import problem in the medical product market, thereby ensuring product pedigree and defending illegal re-packing.



This project has received funding from the European Union's Sevent Framework Programme for research, technological development and demonstration under grant agreement no 26175.


The Seventh Framework Programme for Research and Technological Development (FP7) is the European Union’s main instrument for funding research in Europe between 2007 and 2013 to support economic growth, to enhance quality of life, and to meet social challenges such as improve human health. The SAVEmed project is part of the FP7 programme and covers two main topics of the research area "collaboration": Health and Nano-sciences, Nano-technologies, Materials and new Production Technologies.

The Research Executive Agency supports the project execution.

It manages large parts of the Seventh Framework Programme for Research, Technological Development and Demonstration Activities (FP7) and as an executive agency, it focuses on management tasks outsourced by the Commission and fosters efficiency when addressing the research community's needs. 

Protecting EU-citizens from counterfeit pharmaceuticals